Boston Children’s Hospital Receives $1.5 million for SCD Research, Fred Hutch Names New Endowed...
Weill Cornell Researchers Awarded $9 Million for Lymphoma Research
The National Cancer Institute (NCI) awarded a five-year, $9-million Program Project Grant (P01) to Weill Cornell...
ASH Recommends Changes to Continuing Board Certification, and more
ASH Recommends Changes to Continuing Board Certification
In December 2018, a commission appointed by the American Board of Medical Specialties (ABMS) and other entities released...
The Year in FDA Approvals
In the past year, the U.S. Food and Drug Administration (FDA) approved a record-breaking number of drugs, several of which were indicated for the...
Lenalidomide Maintenance Extends Survival Over Observation Alone in Newly Diagnosed Myeloma
New results from the large phase III Myeloma XI trial confirm that maintenance therapy with lenalidomide improves progressionfree survival (PFS) over observation alone in...
BCMA-Targeting Antibody Associated With Clinical Activity in Previously Treated Myeloma
In a first-in-human trial published in Lancet Oncology, the anti–B-cell maturation antigen (BCMA) antibody GSK2857916 was associated with clinical activity and was reasonably well...
Study of Single-Agent Nivolumab in Patients With Relapsed/Refractory DLBCL Fails to Meet Endpoint
Treatment with single-agent nivolumab was associated with “disappointingly low” response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to...
Combination of Ibrutinib and Nivolumab Appears Similar to Single-Agent Therapy in Early-Phase Trial
According to results from a phase I/II trial published in Lancet Haematology, treatment with a combination of ibrutinib and the checkpoint inhibitor nivolumab was...
Ibrutinib and Palbociclib: A New Combination for Mantle Cell Lymphoma?
The combination of ibrutinib and the CDK-4/6 inhibitor palbociclib could be safely administered to patients with previously treated mantle cell lymphoma (MCL), according to...
Caplacizumab Improves Platelet Normalization Time, Reduces Mortality in Acquired TTP
Adding caplacizumab to standard of care for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) shortened the time to the normalization of platelet counts...
An Advocacy Win for Sickle Cell Disease
An Advocacy Win for Sickle Cell Disease
As part of a multifaceted initiative to address the burden of sickle cell disease (SCD) in the U.S....
Current Issue
March 2019, Volume 5, Issue 4
This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.
